Biomarkers — The Ones That Matter For Optimization

Most people have had blood work done, been told everything looks normal, and still felt tired, foggy, or off. The test was not wrong. The reference range simply answered a different question than the one being asked. A lab reference range describes where the middle 95% of a reference population falls. It is a statistical boundary, not a health target.

This hub covers the markers that change decisions: what to test, what the optimal target is rather than the lab-normal one, how markers group into systems, and how often each is worth repeating. Every guide here states a number you can compare your own result against.

Normal versus optimal — the framework underneath every guide here

A reference range is built by testing a reference population and reporting the central 95%. If that population is broadly unhealthy, the range is broadly unhealthy. Nothing in the method asks whether the result is good — only whether it is common. Normal vs optimal covers the full framework. The table below shows where the two diverge enough to change a decision.

Two cautions on reading this table. Optimal targets are population-level associations, not personal prescriptions — an ApoB of 85 means something different at 35 than at 65 with a family history. And reference ranges themselves vary between labs, because each lab derives them from its own instruments and its own population. Comparing a result from one lab against a target from another introduces error before interpretation even starts.

What standard panels leave out, and why

A typical primary-care panel runs 10–20 analytes: a complete blood count, a metabolic panel, a standard lipid panel, and often TSH. That set is designed to detect or rule out disease efficiently. It is not designed to characterize function.

The systematic omissions follow a pattern. Fasting insulin is absent because it carries no diagnostic threshold for diabetes, while glucose and HbA1c do — even though insulin rises first, often 5–10 years earlier. ApoB is skipped because LDL-C has longer guideline history and a cheaper assay. Lp(a) is skipped because it is not modifiable by lifestyle, which makes it feel actionless despite being a strong independent risk factor. Free testosterone, SHBG, homocysteine, and the omega-3 index are skipped because no reimbursement rule requires them.

None of that means the markers are uninformative. It means the standard panel optimizes for diagnosis under reimbursement constraints, and optimization asks a question reimbursement does not fund.

Group markers by system, not by test tube

A results portal lists markers alphabetically or by the panel they were bundled into. That ordering hides the thing that matters. Grouping by physiological system is what turns a list of values into a picture.

Why a pattern across three markers beats one flagged value

Markers within a system move together because they share upstream drivers. That correlation is what makes patterns readable.

• Metabolic: high fasting insulin plus high triglycerides plus low HDL plus elevated waist circumference is one coherent picture of insulin resistance. Any one of those alone is ambiguous.
• Hormonal: normal total testosterone plus high SHBG plus low free testosterone explains why a "normal" result can accompany real symptoms. Reading total testosterone alone misses it entirely.
• Inflammatory: high ferritin plus high hsCRP usually means inflammation raised the ferritin, not that iron stores are genuinely high. Treating that as iron overload is the wrong intervention.
• Thyroid: elevated TSH plus normal free T4 plus low free T3 points at conversion rather than glandular output, which changes what to do about it.

The practical consequence: a panel is worth more than the sum of its markers only if something reads it as a set. That is the difference between a results dashboard and an interpretation, and it is the main axis on which testing platforms actually differ.

How often to retest

Retest cadence should follow the biology of each marker, not a subscription's billing cycle. HbA1c reflects roughly 90 days of average glucose, so retesting it at six weeks measures mostly the previous quarter and wastes the draw. Fasting insulin, hsCRP, and free testosterone respond within weeks and are worth checking at 8–12 weeks after a change. Vitamin D takes about 8–12 weeks to reach a new steady state on a fixed dose. Lp(a) needs one test, ever.

Draw conditions matter as much as timing. Fasting insulin and glucose require a genuine 10–12 hour fast. Testosterone should be drawn between 7 and 10 a.m., when levels peak — an afternoon draw can read 20–30% lower and produce a diagnosis that a morning draw would not support. Comparing results across different draw times or different labs is a common source of imaginary trends.

Biomarker guides

The advanced markers below are the ones worth adding to a standard panel. Guides to the markers already on the panels most people receive — the red cell indices and the liver and metabolic components of a CMP — follow underneath.

• Effects of chronic inflammation — what inflammaging does over decades, and the cohort effect sizes behind the association
• ApoB — counts atherogenic particles; a stronger cardiovascular risk marker than LDL-C alone
• ApoB test cost — cash price, what insurance and Medicare cover, and how to order it without a physician
• Fasting insulin — the earliest signal of insulin resistance, rarely on standard panels
• IGF-1 blood test — what it measures, why it is drawn instead of growth hormone, and what the draw involves
• IGF-1 levels by age — reference intervals by age and sex, the z-score, and the contested longevity evidence
• Insulin resistance vs prediabetes: two conditions defined on different numbers, and the years between them
• Diabetes symptoms in women — how little of the published symptom list is actually sex-specific, and the four blood-sugar thresholds that decide the diagnosis
• A1c vs fasting glucose — a three-month average against one morning's reading, and what to do when the two disagree
• Metabolic syndrome criteria — the five components, their exact thresholds, and why three definitions disagree
• Metabolic health — the five markers it is measured with, and why changing the cut points halves the share of adults who qualify
• Triglyceride to HDL ratio: the insulin-resistance surrogate you can calculate free from any lipid panel
• HOMA-IR — calculated from fasting insulin and glucose; quantifies resistance before glucose rises
• Homocysteine — associated with cardiovascular and cognitive aging; often a B-vitamin status marker
• Homocysteine levels by age — the one published US age-banded table, and why no authority publishes an age-and-sex one
• Homocysteine and dementia — a reproducible association, and the B-vitamin trials that did not follow it
• Homocysteine and pregnancy — why it falls in a normal pregnancy, and what ACMG and ACOG say about testing after a loss
• Homocysteine test cost — cash prices, and why the reason it is ordered decides whether anyone covers it
• Inflammation blood tests — the full marker inventory, and which combination answers "am I chronically inflamed"
• ESR — the sedimentation rate, its age- and sex-adjusted ranges, and the causes that are not inflammation
• ESR vs CRP — different timescales, and what each discordant pair suggests
• High CRP levels — reading a result above the hsCRP range, and when it is an urgency signal
• Vitamin B12 deficiency — the symptom groups, and why the neurological picture can precede any blood-count change
• Vitamin B12 testing — why serum B12 is a weak test, and what methylmalonic acid settles
• Drug-induced B12 deficiency — metformin, acid suppression, nitrous oxide and surgery, and who should be monitored
• hsCRP — chronic inflammation load, and a major driver of cardiovascular aging
• hs-CRP vs glycans — a state marker against a trait marker, and which question each one answers
• Lp-PLA2 — an arterial-inflammation marker that two randomised trials failed to turn into a treatment target
• Lp(a) — inherited risk factor; test once, since it rarely changes with lifestyle
• Lp(a) vs ApoB — why neither LDL-C nor ApoB isolates Lp(a), and which to order first
• Lp(a) test fasting and prep — what actually distorts the result, and why sources disagree about fasting
• Lp(a) test cost — cash prices at both national labs, and the Medicare screening exclusion
• Normal vs optimal ranges — the framework underneath every guide here
• Omega-3 index — red-cell EPA and DHA; more accurate than tracking fish oil intake
• SHBG — binds testosterone and controls bioavailability; explains normal-total, low-free results
• Testosterone levels by age — where the published reference bands stop stratifying, and why Labcorp and Quest disagree on the adult range
• Estradiol levels in men — the published interval, and why the assay on the report decides what the number means
• Ultrasensitive estradiol test — the LC-MS/MS method itself, and the three groups whose results an immunoassay cannot be trusted for
• DNA biomarkers — which genetic results change medical care, and which only describe background risk
• Environmental toxin testing — which exposures a blood or urine panel can actually quantify, and which clear too fast to measure
• Heavy metals test — which sample is valid for which metal, and the two methods to avoid
• Lipid panel: the five lines on a standard report, and why LDL is calculated rather than measured
• Lipid panel fasting: when a fasting sample still matters, and why alcohol distorts it more than breakfast
• Non-HDL cholesterol: total minus HDL, counting every atherogenic particle with no fasting sample needed
• At-home A1c tests: mail-in kits against instant analyzers, and what each format can support
• Thyroid panel: which of TSH, free T4, free T3 and antibodies to order, and what blood work cannot see
• Normal thyroid test with symptoms: what a normal TSH rules out, and the four causes to test next

Markers already on your standard panel

• CMP blood test — what a comprehensive metabolic panel measures, the six common misreadings, and the gaps it leaves
• CO2 blood test: the metabolic-panel line that measures bicarbonate rather than the gas you breathe out
• Chloride — the electrolyte that moves with bicarbonate, and what the anion gap does with the pair
• Creatine kinase: the muscle enzyme a hard workout raises for days
• Vitamin D blood test: which of the two assays to order, and where the 20 and 30 ng/mL thresholds came from
• ALT — liver-cell injury, and the clearest case of a reference range more generous than the evidence supports
• Alkaline phosphatase — grouped with the liver tests but produced equally by bone; GGT identifies the source
• MCV — average red cell size; sorts anaemia towards iron on one side, B12 and folate on the other
• RDW — red cell size variability; moves earlier than MCV, and tracks mortality risk inside the normal range
• MCHC — haemoglobin concentration per cell; insensitive to early iron deficiency, and a high result is usually a sample artifact
• MCH — average haemoglobin per red cell; confirms the story MCV tells, and outlasts it when a sample is delayed
• RBC — the red cell count every index above is derived from; a high count is usually contracted plasma, not extra cells
• MPV — average platelet size; only interpretable read against the platelet count, and it drifts in the tube
• AST — cell injury, but not liver-specific; muscle, heart and a haemolysed sample all raise it
• GGT — the marker that splits a raised alkaline phosphatase into liver or bone, and the most alcohol-sensitive enzyme on a panel
• Bile acid test — the direct bile-flow marker, ordered mainly for itching in pregnancy and not part of a standard liver panel
• BUN — filed as a kidney test, but hydration and dietary protein move it as often as the kidneys do
• eGFR — calculated from creatinine rather than measured, which is why muscle mass and creatine shift it
• Kidney function test — what the panel actually contains, whether it needs a fast, and the early damage it cannot see
• Urinalysis — the three-part urine test: what the visual, dipstick and microscopic checks look at, and what normal looks like
• Cystatin C — the filtration marker muscle mass does not move, and the situations where it changes the answer
• Estradiol blood test — the ranges by sex and menopausal status, and why a standard immunoassay misreads a low result
• TSH — a pituitary hormone, not a thyroid one; the clearest case where lab-normal and optimal diverge
• TIBC — with UIBC and transferrin saturation, the iron panel that stays readable when ferritin is distorted by inflammation
• Ferritin — iron stores, and the marker that falls first; inflammation pushes it back up and hides the deficiency
• Uric acid — the gout and kidney-stone marker; usually a story about kidney excretion and insulin resistance rather than diet
• HbA1c: the share of hemoglobin carrying glucose, with half the value coming from the previous 30 days
• False A1c results: iron deficiency raises it, blood loss and kidney disease lower it, and what to order instead
• Creatinine: a muscle marker the kidneys clear, which is why creatine and muscle mass move it
• WBC blood test — the total white cell count, the unit systems the same result is printed in, and why the differential carries the meaning
• High white blood cell count — the benign drivers that come before infection, and the magnitudes that change what a clinician does
• Neutrophils — the absolute neutrophil count, the neutropenia thresholds, and benign ethnic neutropenia
• Hematocrit — HCT against PCV and haemoglobin, and the hydration artefact that moves all three
• Potassium — the line printed as K, why its range is so narrow, and which medications move it
• False high potassium — haemolysis, the tourniquet and the transport delay, and how a spurious result is told apart from a real one
• Bilirubin — where the pigment comes from, and why Gilbert syndrome explains most mildly raised results
• Direct vs indirect bilirubin — a measurement term mistaken for a biological one, and what the split narrows down
• Albumin — what a low or high albumin result means, and why the range differs by source
• Total protein — albumin plus globulins, and what a high or low result points to
• High liver enzymes — the common causes of a raised ALT, AST, ALP or GGT, and what happens next
• VLDL cholesterol — estimated from triglycerides rather than measured, and where that estimate breaks
• LDL to HDL ratio — what the ratio adds over either number alone, and where ApoB and non-HDL sit against it

Which platforms test these

Coverage varies widely, and more markers does not automatically mean more useful. Every platform reviewed on this site is listed, alphabetically: Fountain Life (200+, clinic-based), Function Health (100+, self-directed), Hone Health (hormone panel plus therapy safety markers), InsideTracker (~48, with a recommendation engine), Lifeforce (~40 plus hormones), Marek Health (a la carte — you select the panel), Maximus (hormone panel plus therapy safety markers), Opt Health (55+, physician-led), and Superpower (100+, app-first). Ordering carries no editorial meaning. The full side-by-side is on the platform hub, ordered alphabetically.

First-mention official sites, alphabetically: Fountain Life, Function Health, Hone Health, InsideTracker, Lifeforce, Marek Health, Maximus, Opt Health, Superpower.

Related

• Biological age — what the tests measure and what they do not
• Doctor-led options — programs where a clinician reads the panel with you
• Longevity platforms compared — every option on the same rubric
• Supplement guides — what to take once you know what is low